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Hereditary nonpolyposis colorectal cancer (HNPCC) is caused by inherited mutations in DNA mismatch-repair
genes, most commonly MLH1 or MSH2. The role MSH6 plays in inherited cancer susceptibility is less well deﬁned.
The aim of this study was to investigate the penetrance and expressivity of MSH6 mutations in kindreds ascertained
through endometrial cancer probands unselected for family history. Detailed pedigrees were constructed for six
MSH6 mutation carriers. All reported cancers and precancers were conﬁrmed, and tissues were obtained when
available. Tumors were analyzed for microsatellite instability (MSI) and for expression of MSH2, MLH1, and
MSH6. MSH6 mutation status was determined for 59 family members. Of these 59 individuals, 19 (32%) had
conﬁrmed cancers and precancers. There was an excess of mutation carriers among the 19 affected family members
(11 [58%] of 19) compared with those among the 40 unaffecteds (8 [20%] of 40, , odds ratio p 5.5,Pp .0065
95% CI p 1.66–18.19). In four of the seven tumors analyzed from mutation carriers other than the probands,
MSI and/or MMR protein expression was consistent with the involvement of MSH6. Overall estimated penetrance
of the MHS6 mutations was 57.7%. Of the tumors in mutation carriers, 78% were part of the extended HNPCC
spectrum. This study demonstrates that MSH6 germline mutations are, indeed, associated with increased cancer
risk and that the penetrance of mutations may be higher than appreciated elsewhere. A combination of MSI and
immunohistochemistry analyses may be helpful in screening for MSH6 mutation carriers.
Hereditary nonpolyposis colorectal cancer (HNPCC) is
an autosomal dominant cancer-susceptibility syndrome
characterized by early onset cancers of the colorectum,
endometrium, small bowel, ureter, and renal pelvis (Am-
sterdam criteria II; see Vasen et al. [1999]). Additional
extracolonic lesions associated with the syndrome in-
clude cancers of the stomach, ovary, brain, and hepa-
tobiliary tract and benign sebaceous adenomas (Vasen
et al. 1999). HNPCC is caused by inherited mutations
in DNA mismatch-repair genes, most commonly involv-
ing MLH1 (MIM 120436) or MSH2 (MIM 120435)
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(Fishel et al. 1993; Bronner et al. 1994). Defective DNA
mismatch repair in HNPCC-associated tumors results in
the microsatellite instability (MSI) tumor phenotype
(Aaltonen et al. 1993). MSI is found in 190% of colo-
rectal tumors and ∼75% of endometrial tumors asso-
ciated with HNPCC (Risinger et al. 1993; Fujiwara et
al. 1998).
Germline mutations in MSH6 (MIM 600678) have
been reported elsewhere as an uncommon cause of
HNPCC (Miyaki et al. 1997; Wijnen et al. 1999; Wu et
al. 1999). In fact, most MSH6 mutations have been
found in kindreds with suspected HNPCC that do not
fulﬁll the classic diagnostic criteria (Kolodner et al. 1999;
Shin et al. 1999; Wijnen et al. 1999; Wagner et al. 2001).
MSH6 kindreds are often characterized by multiple en-
dometrial cancers, low penetrance of colorectal cancer,
and older age at cancer diagnosis. An additional distin-
guishing feature of MSH6-associated HNPCC is the ob-
servation that many cancers arising in mutation carriers
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Table 1
Details of Family Size, Number of Individuals with Tumors, and MSH6 Mutation Status for Seven
Kindreds of MSH6 Germline Mutation Carriers
NO. OF RELATIVES WITH
KNOWN MUTATION STATUS
KINDREDS
NO. OF REPORTED
RELATIVES
NO. OF RELATIVES WITH
CANCERS AND
PRECANCERS
REPORTED/CONFIRMEDa
Affected Carriers/
Noncarriersa,b
Unaffected Carriers/
Noncarriersa
ID:
1524 71 12/12 3/2 5/4
1064 57 7/4 1/2 0/7
1497 2 1/0 0/0 0/0
1319 27 8/0 0/0 0/2
1335 27 9/4 2/1 2/3
1401 58 9/8 5/2 1/11
1389 38 7/1 0/1 0/5
All 280 53/29 11/8 8/32c
a Mean age of relatives with cancers and precancers reported/conﬁrmed is 58.4/63.8 years, of affected
carriers/noncarriers is 65.6/64.9 years, and of unaffected carriers/noncarriers is 42.8/47.0 years.
b Affected includes only conﬁrmed cancers and precancers.
c Of the affected relatives, 11 of 19 were mutation carriers, whereas 8 of 40 unaffected relatives had
an MSH6 mutation ( , Fisher’s exact test).Pp .0065
exhibit an MSI-low (MSI-L) or MS-stable (MSS) tumor
phenotype (Wijnen et al. 1999; Wu et al. 1999; Berends
et al. 2002). Functional redundancy in the DNA mis-
match-repair system could explain the less extensiveMSI
observed in tumors in MSH6 germline mutation carriers
compared with the MSI of MSH2- or MLH1-associated
cancers (Acharya et al. 1996; Marsischky et al. 1996).
The exact role of MSH6 germline mutations in in-
herited cancer susceptibility is uncertain at this time.
Whether inherited defects in MSH6 cause HNPCC,
when some MSH6-associated tumors do not appear to
be deﬁcient in DNA mismatch repair, is a subject of
debate. One possible explanation is that MSH6 defects
may affect pathways preceding mismatch-repair func-
tion (Kariola et al. 2002). Alternatively, some of the
MSH6 mutations found in kindreds with atypical
HNPCC may not be the cause of their cancer suscep-
tibility but, rather, an incidental ﬁnding. Lastly, it is also
possible thatMSH6mutations seemingly associatedwith
MSS tumors cause low-level MSI that is not detected by
the NCI consensus panel (Boland et al. 1998) used by
most investigators.
We investigated the penetrance and expressivity of
presumed pathogenic MSH6 germline mutations in
seven kindreds identiﬁed through endometrial cancer
probands that were not ascertained on the basis of family
or medical history (Goodfellow et al. 2003). The loss-
of-function mutations in these kindreds are as follows
(kindred identiﬁcation numbers are in boldface): 1401
L634Z; 1335 R911Z; 1497 R911Z; 1389 frameshift,
insert TA at codon 1066; 1064 alanine insertion, insert
CTG at codons 1163/1164; 1319 frameshift, del CAAG
at 1320/1321, and 1524 frameshift, insert TCAAAAG-
GGACATAGAAAA at 1320. All of the probands’ can-
cers had high-level microsatellite instability (MSI-H).
Detailed family histories were obtained for six of the
seven probands. Case 1497 declined to participate in the
study, and we had only the reported cancer status for
her parents. Information regarding cancers or precancers
was obtained for 278 relatives of the 6 other endometrial
cancer probands (mean 46 per family, a range of 27–
71) over four generations. Reported cancers, possible
precancers (including colonic polyps and endometrial
hyperplasia), and any tumors of uncertain malignant po-
tential, as well as ages at diagnosis, were veriﬁed by a
review of medical records, pathology reports, and/or
death certiﬁcates when available. Among 53 relatives
(including 1 parent of case 1497) reported as having
cancers or precancers, 29 cases (55%) were conﬁrmed
via medical record review, yielding detailed information
on 32 (54%) of 59 reported lesions.
MSH6 mutation status was determined for 59 rela-
tives (21% of those reported). The PCR primers and
methods used to determine mutation status are included
in table A1 (online only). The mean age of these 59
relatives was 51.3 years. Of the 59 family members, 19
(32%) had conﬁrmed cancers or precancers (affected).
The remaining 40 relatives we analyzed were unaffected
by any conﬁrmed cancers or precancers. There was a sta-
tistically signiﬁcant excess of MSH6 mutation carriers
among the affected family members. As shown in table
1, 11 (58%) of 19 affected relatives were mutation car-
riers, whereas 8 (20%) of 40 unaffected relatives had an
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MSH6 mutation ( , odds ratiop 5.5, 95% CIPp .0065
p 1.66–18.19, two-tailed Fisher’s exact test).
Overall, the affected family members were older than
the unaffected ones. The mean age at diagnosis of the
19 affected family members was 64.7 years, whereas the
unaffected family members had a mean age of 46.1 years
( , Student’s t-test). A similar age differencePp .0018
was found between the mean ages of the 11 affected
mutation-carriers (65.6 years) and the 8 unaffected mu-
tation-carriers (42.8 years). Table 1 summarizes the in-
formation on conﬁrmed cancers and mutation status for
each of the seven kindreds. The pedigrees for the seven
kindreds, including mutation status and age at onset of
tumors, are presented in ﬁgure 1.
In an effort to further determine whether inherited
MSH6 mutations confer an increased risk for cancers in
relatives, we compared the rates of conﬁrmed cancers in
the ﬁrst-degree relatives of our 6 MSH6 probands and
40 MSS endometrial cancer probands from the same
patient series (described in Whelan et al. [2002]). We
reasoned that this MSS cohort is representative of spo-
radic endometrial cancer families. As the risk of devel-
oping cancer increases with age, only ﬁrst-degree rela-
tives 160 years old and free from cancer or individuals
affected with cancer at any age were considered infor-
mative and were included in the analysis. A signiﬁcantly
higher number of cancers were found in ﬁrst-degree rel-
atives of the 6 MSH6 probands than in those of the 40
MSS probands. Among 16 informative ﬁrst-degree rel-
atives in the MSH6 cohort, 7 cancers were conﬁrmed,
versus 17 conﬁrmed cancers in 150 informative ﬁrst-
degree relatives in the MSS cohort (44% vs. 11.3%,
, two-tailed Fisher’s exact test).Pp .0027
We assessed tumors forMSI and mismatch-repair pro-
tein expression by immunohistochemistry. Archival tis-
sue specimens were available for seven cancers/precan-
cers from seven MSH6 mutation carriers. Results of the
combined MSI analysis and immunohistochemistry for
MSH6 are presented in table 2. For three of the seven
mutation carriers (1064:III-1 with a squamous cell car-
cinoma [SCC] of the tongue, 1524:II-2 with prostate
cancer, and 1335:II-3 with a colonic adenoma), the mo-
lecular analyses did not suggest an association between
MSH6 germline mutation and the development of their
tumors. The specimens showed no evidence of MSI at
any marker and stained positively for all threemismatch-
repair proteins. Because the MSI phenotype is variable
in MSH6 mutation carriers, it may be unreliable to use
solely MSI to make a connection between mutation and
disease, but, if the expression data is considered as well,
it seems unlikely that these three tumors have a defect
in mismatch repair.
For two of the seven mutation carriers (1524:III-2
with a pituitary adenoma and 1335:II-2 with colon can-
cer) the molecular analysis of the tumors suggested a
causative role for MSH6. The pituitary adenoma had
MSI at BAT25 (ﬁg. 2A) as well as loss of the wild-type
copy of MSH6 (ﬁg. 2B), whereas the colon cancer had
MSI at all markers (data not shown). MSH6 staining
was absent for both the pituitary adenoma and colon
carcinoma (ﬁg. 2C and additional data, not shown). For
the remaining two mutation carriers (1524:II-3 with a
colonic adenoma and 1401:III-4 with prostate cancer),
evidence for the involvement ofMSH6was inconclusive.
The adenoma from 1524:II-3 showed focally positive
staining for MSH6 but had MSI at D17S250 (data not
shown). The prostate carcinoma from 1401:III-4 had
absent MSH6 staining (data not shown); however, there
was insufﬁcient tissue to perform MSI analysis on this
tumor.
The overall penetrance of MSH6 germline mutations
was 69.2% (18 affected individuals among 26 mutation
carriers, including the probands), on the assumption that
all cancers/precancers were associated with MSH6 mu-
tation. Figure 3 illustrates the fraction of penetrant fam-
ily members plotted against age in years. The estimated
penetrance decreases to 57.7% if we exclude the three
affected mutation-carriers for whom no evidence for
MSH6 involvement in their tumors was found.
The different types of conﬁrmed cancers and precan-
cers found in MSH6 mutation carriers and noncarriers,
excluding the probands, are presented in table 3. Over-
all, 9 (69%) of 13 cancers/precancers in mutation car-
riers were HNPCC-associated lesions in accordancewith
the ICG Research Criteria (Vasen et al. 1999), compared
with 4 (50%) of 8 cancers/precancers in the nonmutation
carrier group. As described elsewhere (Buttin et al.
2004), two of the seven probands, 1064 and 1497, had
second HNPCC-associated cancers: rectal and ovarian
carcinomas, respectively.
Although the link between MSH2, MLH1, and
HNPCC has been ﬁrmly established, the exact role of
MSH6 in inherited cancer susceptibility continues to
evolve. MSH6 germline mutations are a cause of
HNPCC, although most families with mutations do not
conform to the Amsterdam II criteria. Screening for
MSH6 mutation is recommended for kindreds with sus-
pected inherited cancer susceptibility suggestive of
HNPCC who test negative for MSH2 and MLH1 germ-
line mutations (Lynch and de la Chapelle 2003). It
should be emphasized that mutations in MSH6 are more
frequent in kindreds that fail to meet HNPCC diagnostic
criteria. The true incidence ofMSH6 germline mutations
in HNPCC is yet to be determined.
Efforts to deﬁne the role of MSH6 in HNPCC, and
in cancer susceptibility in general, have been hampered
by the fact thatMSH6mutations may be associatedwith
tumors that lack features usually associated with defec-
tive DNA mismatch repair and the fact that kindreds
segregating MSH6 mutations may be lacking the clinical
Figure 1 MSH6 kindreds. Kindred 1524, I1 Hodgkin lymphoma, age 58; I2 Hodgkin lymphoma, age 44; I3 lung cancer, age 36;
I4 laryngeal cancer, age 61; I5 colon cancer, age 92; I6 endometrial cancer, age 65; II1 lung cancer, age 69; II2 prostate cancer, age
73; II3 colonic tubular adenoma, age 69; II4 lung cancer, age 74; II5 lung cancer (small cell), age 71, and lung cancer (oat cell), age 78;
III1 endometrial cancer, age 46; III2 atypical pituitary adenoma, age 38. Kindred 1401, I1 colon cancer, age 80; II1 pancreatic cancer,
age 73; II2 cholangiocarcinoma, age 86; II3 glioblastoma, age 80s; II4 uterine cancer, age 40s (unconﬁrmed), and adenomatous colon
polyps, age 86; II5 renal cell cancer, age 50s (unconﬁrmed), and breast cancer, age 97; III1 endometrial cancer, age 57; III2 basal cell
cancer, age 56; III3 adenomatous colon polyps, age 53; III4 prostate cancer, age 62, and adenomatous colon polyps, age 66. Kindred 1319,
I1 skin cancer, age 60s; II1 cancer, unknown primary, age 40s; II2 cancer, unknown primary, age 61; II3 cancer, unknown primary, age
40; II4 cancer, unknown primary, age 60; II5 multiple myeloma, age 70s; III1 endometrial cancer, age 40s; III2 endometrial cancer, age
74; III3 skin cancer, age 50s. Kindred 1064, II1 breast cancer, age late 20s; II2 brain cancer, age 60s; II3 oat cell lung cancer, age 66;
II4 ovarian cancer, late 30s, and colon cancer, age 40s; II5 rectal cancer, age 65; III1 tongue squamous cell carcinoma, age 63; III2
endometrial cancer, age 53, and rectal cancer, age 61; IV1 medulloblastoma, age 3. Kindred 1497, I1 esophageal cancer, age unknown;
II1 endometrial cancer, age 52, and ovarian cancer, age 52. Kindred 1335, I1 lung cancer, age unknown; I2 liver cancer, age unknown;
I3 prostate cancer, age 40s; I4 breast cancer, age 60; I5 prostate cancer, age 60; I6 endometrial cancer, age 50s; II1 pancreatic cancer,
age 71; II2 endometrial cancer, age 35, and colon cancer, age 67; II3 adenomatous colon polyps, age 65; III1 endometrial cancer, age 44.
Kindred 1389, II1 endometrial cancer, age 30; III1 cancer, unknown primary, age unknown; III2 lung cancer, age 60s; III3 breast cancer,
age 70s; III4 bladder cancer, age 72; III5 endometrial cancer, age 61; III6 cancer, unknown primary, age 76; IV1 cancer, unknown
primary, age unknown.
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Table 2
Results of MSI Analysis and IHC of MMR Proteins on Available Tumors of MSH6 Mutation Carriers
MSI MARKERS IHC
KINDRED ID
RELATIONSHIP
TO PROBAND TUMOR TYPEa
AGE AT
DIAGNOSIS D17S250 D2S123 D5S346 BAT25 BAT26 BAT40
MSI
STATUS MSH6 MSH2 MLH1
1064:III-1 Brother SCC tongue 63 NI NL NL NI NI NI MSS   
1524:II-3 Mother Colonic adenoma 69 MSI NL NL NI NI NI MSI-L Focal weak  
1524:II-2 Maternal uncle Prostate ca 73 NL NL NL NI NI NL MSS   
1524:III-2 Sister Pituitary adenoma 38 LOH LOH NL MSI NI NI MSI-L   
1335:II-2 Mother Colon ca 67 MSI MSI MSI MSI MSI MSI MSI-H   
1335:II-3 Maternal uncle Colonic adenoma 65 NL NL NI ND NI NI MSS   
1401:III-4 Maternal cousin Prostate ca 62 ND ND ND ND ND ND ND  ND 
NOTE.—MSI analysis was performed using ﬁve consensus markers (Boland et al. 1998). Since MSH6 mutations tend to have lower levels of MSI and MSI is
more frequently found in mononucleotide repeats, an additional mononucleotide marker (BAT40) was typed. Samples were classiﬁed as MSI-H if instability was
detected at two or more consensus markers, as MSI-L if instability was conﬁned to one consensus marker, and as MSS if none of the consensus markers revealed
instability. IHC for MLH1, MSH2, and MSH6 was performed with the use of 5-mm thick parafﬁn sections mounted on charged slides, as described elsewhere (Buttin
et al. 2004). Sections of normal appendix served as external positive controls. Nuclear staining was read as positive (), and absence of nuclear staining of any of
these was read as negative (). Abbreviations in the table are as follows: ca p carcinoma, LOH p loss of heterozygosity, NL p no loss, NI p not informative,
and ND p no data.
a Includes only conﬁrmed cancers and precancers (see “Subjects and Methods”).
hallmarks of HNPCC. Hence, screening on the basis of
either tumor MSI status or cancer family history may
fail to identify a subset of patients with MSH6 germline
defects. There is a clear need to further characterize the
natural history of MSH6 germline mutations, to better
deﬁne MSH6-associated HNPCC and, ultimately, to de-
vise appropriate identiﬁcation, clinical screening, and
treatment strategies.
We evaluated seven kindreds in an effort to clarify the
role of MSH6 germline mutations in inherited cancer
susceptibility. Unlike prior studies, we investigated fam-
ilies of MSH6 germline mutation carriers that were iden-
tiﬁed independent of family history or age at diagnosis.
The MSH6 germline mutations were detected in women
with MSI-H endometrial cancers. Given the reported as-
sociation between MSH6 germline mutations and MSI-
L or MSS tumors (Wu et al. 1999; Wagner et al. 2001;
Berends et al. 2002), our results may suggest that the
mutations are different from those described elsewhere.
It is possible that kindreds ascertained through probands
with MSI-L or MSS tumors have different penetrance
and expressivity from that of the kindreds we studied.
Regardless, the family histories of our MSH6 germline
mutation carriers underscore the uncertainty as to who
should be screened for MSH6 germline mutations. We
note a heterogeneous spectrum of cancers and precancers
(colonic adenomas). Two kindreds (1335 and 1401)
could be classiﬁed as atypical HNPCC families (because
of two, as opposed to three, ﬁrst-degree relatives with
endometrial/colon cancer in kindred 1335 and because
of older age at diagnosis in kindred 1401). However, the
other four kindreds may not have been identiﬁed as fam-
ilies with increased risk for inherited cancer susceptibility
on the basis of family history alone.
The families we studied have many features in com-
mon with MSH6 kindreds that have been described else-
where. However, we detected only 1 case of colon car-
cinoma among 13 different types of cancers and
precancers found in 11 affected mutation-carriers (ex-
cluding the probands). This ﬁnding conﬁrms the sug-
gestion that MSH6 kindreds may have a lower pene-
trance of colorectal cancer (Wijnen et al. 1999) in
comparison with that of MSH2 and MLH1 HNPCC
kindreds. We did ﬁnd an increased number of colonic
adenomas in the mutation carriers compared with the
number found in noncarriers (four vs. one), possibly
suggesting increased potential for carcinogenesis with
very slow progression.We found one case of endometrial
cancer among the ﬁve female affected mutation-carriers
with a mean age of 65 years, in addition to the six known
endometrial cancers in the probands. However, many of
the female family members in the older generations had
hysterectomies at an early age for benign reasons. Other
authors have reported a predominance of endometrial
cancers (52%–73%) in femaleMSH6 germlinemutation
carriers (Wijnen et al. 1999; Wagner et al. 2001; Berends
et al. 2002). Including our six endometrial cancer pro-
bands, the incidence of endometrial cancer in female
mutation carriers in this study (7 [64%] of 11) conﬁrms
this suggestion.
Although the comparison was limited by small num-
bers, there was no signiﬁcant difference between the
types of cancers found in mutation carriers and those
found in nonmutation carriers (table 3), with the ex-
ception of an excess of colonic adenomas in themutation
carriers. This clinical heterogeneity (variable expressiv-
ity) underlines the limitations of screening patients for
a family history suggestive of HNPCC or atypical
HNPCC to detect those with germline MSH6 defects.
Our data demonstrate that MSH6 germline mutations
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Figure 2 Molecular analysis of an atypical pituitary adenoma
that arose in an MSH6 mutation carrier. A, MSI analysis. Instability
at the BAT25 marker is seen as a subtle increase in the size of the PCR
products in the tumor DNA (T), compared with those in the normal
DNA (N), and as a novel insertion (arrow). The tumor and matched
normal specimens show identical patterns with the BAT26 andD5S346
markers. B, Mutation analysis revealing loss of the wild-type allele in
the tumor (arrowhead). C, Immunohistochemistry revealing loss of
expression ofMSH6 in the proband’s endometrial cancer (upper panel)
and in the atypical pituitary adenoma (lower panel). Note the positive
staining with MLH1 and MSH2 in both tumors.
Figure 3 Penetrance ofMSH6mutations in 26mutation carriers.
The seven endometrial cancer probands are included in one plot (solid
line) and are excluded in the other plot (dashed line).
are, indeed, associated with increased cancer risk. Al-
hough the mouse studies by Edelmann et al. (1997) sug-
gest that MSH6 mutation is associated with highly pen-
etrant, late-onset disease, studies of humans, to date,
could not truly address onset and penetrance, as the
majority of kindreds evaluated were chosen on the basis
of increased familial risk. Screening patients for inherited
cancer susceptibility associated with MSH6 mutation
perhaps should include an awareness of the overall in-
creased numbers of relatives with any cancer at any age,
rather than a speciﬁc focus on HNPCC-type disease. The
exact tumor spectrum associated withMSH6 defects will
require further investigation.
Lastly, the results of our molecular correlative studies
suggest the utility of immunohistochemistry in the as-
sessment of the role of MSH6 in tumorigenesis. We dem-
onstrated a very consistent pattern of absent staining for
MSH6 in all endometrial tumors of our seven probands,
whereas both MSH2 and MLH1 staining remained in-
tact. These ﬁndings conﬁrm a report by de Leeuw et al.
(2000), in which the authors described consistent iso-
lated absence of MSH6 staining in tumors from MSH6
germline mutation carriers, consistent absence of both
MSH2 and MSH6 staining in MSH2 mutation carriers,
and inconsistent results in tumors fromMLH1mutation
carriers. De Leeuw et al.’s study (2000) showed more
variability with regard to MSI than did ours. As noted,
all of our index endometrial cancers were MSI-H, and
the mutations we evaluated are all presumed loss-of-
function defects. However, some of the other tumors
found in MSH6 mutation carriers with absent or ques-
tionable MSH6 staining were MSI-L (the colonic ade-
noma in 1524:II-3 had MSI at D17S250, and the pi-
tuitary adenoma in 1524:III-2 had MSI at BAT25), and
none were MSS (table 2). The combination of MSI and
immunohistochemistry (IHC) analysis was able to dem-
onstrate that three tumors arising in MSH6 mutation
carriers, (a SCC of the tongue in 1064:III-1, a prostate
carcinoma in 1524:II-2, and a colonic adenoma in 1335:
II-3) were unlikely to be associated with loss of MSH6
function.
Our data provide only an estimate of the penetrance
of MSH6 germline mutations because we were unable
to obtain tissue on all conﬁrmed cancers in mutation
carriers. Therefore, it is possible that we may have over-
estimated the penetrance of the mutations. However, our
conservative estimate of 57.7% total penetrance (ex-
cluding the three affected mutation-carriers without any
evidence of MSH6 involvement in their tumors) is still
higher than elsewhere appreciated. As expected, the
mean age of cancer diagnosis among affected mutation-
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Table 3
Summary of Cancers and Precancers Found in MSH6
Mutation Carriers Versus Noncarriers
PRECANCER/CANCERa,b
NO. IN
MSH6 MUTATION
CARRIERS
NO. IN
NONCARRIERS
Colonic adenoma 4 1
Colon ca 1 1
Endometrial ca 1 0
Rectal ca 0 1
Hepatobiliary ca 1 0
Bladder ca 0 1
Brain ca 2 1
Pancreatic ca 0 1
Lung ca 0 1
Skin ca 1 1
Prostate ca 2 0
Breast ca 1 0
All HNPCC-associated 9 (of 13) 4 (of 8)
a ca p carcinoma.
b Tumors in italics are associated with HNPCC in accordance
with the ICG deﬁnition of “Lynch Syndrome” (Vasen et al.
1999).
carriers (65.6 years) is signiﬁcantly higher than the mean
age reported for HNPCC patients with MLH1 orMSH2
mutations (41–48 years, depending on cancer type; see
Wagner et al. [2001]).
In summary, our study represents an unbiased analysis
of the natural history, including penetrance and expres-
sivity, of MSH6 germline mutations. We demonstrate an
increased cancer risk associated with these mutations,
although the exact tumor spectrum remains to be elu-
cidated. Our data conﬁrm other reports that someMSH6
kindreds fall under the extended or atypical HNPCC
spectrum and also show that other kindreds are char-
acterized by tumors only recently implicated in HNPCC,
such as prostate cancer (Soravia et al. 2003), or not
previously associated with HNPCC, such as an atypical
pituitary adenoma. The overall penetrance of MSH6
germline mutations may be as high as 58%, and, as
noted by other investigators, the age at onset of cancers
is later than is seen in kindreds segregating MSH2 and
MLH1 mutations. Neither tumor MSI status, young age
at cancer diagnosis, nor a family history suggestive of
atypical or classic HNPCC will identify all MSH6 mu-
tation carriers. A combination of MSI and IHC analyses
for mismatch-repair–protein expression in tumor tissue
may be helpful in screening for possible mutation
carriers.
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